These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17227973)

  • 1. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism.
    Edwards JL
    JAMA; 2007 Jan; 297(3):262; author reply 263. PubMed ID: 17227973
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism.
    Harrington DW; Jindeel A
    JAMA; 2007 Jan; 297(3):262; author reply 263. PubMed ID: 17227972
    [No Abstract]   [Full Text] [Related]  

  • 3. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism.
    Zhan H; Zheng H
    JAMA; 2007 Jan; 297(3):261-2; author reply 263. PubMed ID: 17227970
    [No Abstract]   [Full Text] [Related]  

  • 4. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism.
    Bhala N; Shah A; King A; Molugu C
    JAMA; 2007 Jan; 297(3):261; author reply 263. PubMed ID: 17227971
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK; Dembitzer AD; Sanders GD; Garber AM
    Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 8. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme.
    Hull RD; Pineo GF
    Int Angiol; 1998 Sep; 17(3):131-4. PubMed ID: 9821024
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
    Bernardi E; Prandoni P
    Curr Opin Pulm Med; 2005 Sep; 11(5):363-7. PubMed ID: 16093806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New heparin is no heavyweight.
    Feinberg AW
    Health News; 2000 Aug; 6(8):5-6. PubMed ID: 10948870
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of low-molecular-weight heparins for deep venous thrombosis.
    Reilly BM; Evans A
    Ann Intern Med; 2000 Mar; 132(6):508-9. PubMed ID: 10733457
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism.
    Sprague S; Cook DJ; Anderson D; O'Brien BJ
    Thromb Res; 2003; 112(4):193-201. PubMed ID: 14987911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LMW heparins: from transition to fruition.
    Check W
    CAP Today; 1999 Jun; 13(6):1, 62, 66-7; passim. PubMed ID: 10539128
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for venous thromboembolism. What are the current options?
    Yacovella T; Alter M
    Postgrad Med; 2000 Sep; 108(4):43-6, 51-4. PubMed ID: 11021258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.